Teva Announces Collaboration to Commercialize Formycon's Biosimilar Candidate to Eylea(R) (aflibercept) in major parts of Europe and in Israel

MLA

“Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea(R) (Aflibercept) in Major Parts of Europe and in Israel.” Thomson Reuters ONE, 13 Jan. 2025. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.823267228&authtype=sso&custid=ns315887.

APA

Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea(R) (aflibercept) in major parts of Europe and in Israel. (2025, January 13). Thomson Reuters ONE.

Chicago

Thomson Reuters ONE. 2025. “Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea(R) (Aflibercept) in Major Parts of Europe and in Israel,” January 13. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.823267228&authtype=sso&custid=ns315887.